Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | NIMA-related kinase 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | NIMA related kinase 4 | 0.0022 | 1 | 0.5 |
Toxoplasma gondii | NEK kinase | 0.0022 | 1 | 0.5 |
Trypanosoma cruzi | NIMA-related kinase, putative | 0.0022 | 1 | 1 |
Plasmodium vivax | serine/threonine-protein kinase NEK4, putative | 0.0022 | 1 | 0.5 |
Leishmania major | protein kinase, putative | 0.0022 | 1 | 0.5 |
Trypanosoma cruzi | Serine/threonine-protein kinase NEK16, putative | 0.0022 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0022 | 1 | 0.5 |
Trypanosoma brucei | NIMA-related protein kinase | 0.0022 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0022 | 1 | 0.5 |
Echinococcus granulosus | serine:threonine protein kinase Nek1 | 0.0021 | 0 | 0.5 |
Echinococcus multilocularis | serine:threonine protein kinase Nek1 | 0.0021 | 0 | 0.5 |
Trypanosoma cruzi | Serine/threonine-protein kinase NEK11, putative | 0.0022 | 1 | 1 |
Trypanosoma cruzi | Serine/threonine-protein kinase NEK11, putative | 0.0022 | 1 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0022 | 1 | 0.5 |
Leishmania major | serine/threonine-protein kinase, putative | 0.0022 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0022 | 1 | 0.5 |
Plasmodium falciparum | NIMA related kinase 2 | 0.0022 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0022 | 1 | 0.5 |
Toxoplasma gondii | NEK kinase | 0.0022 | 1 | 0.5 |
Trypanosoma brucei | Serine/threonine-protein kinase NEK11, putative | 0.0022 | 1 | 0.5 |
Trypanosoma brucei | Serine/threonine-protein kinase NEK16, putative | 0.0022 | 1 | 0.5 |
Toxoplasma gondii | NEK kinase | 0.0022 | 1 | 0.5 |
Leishmania major | protein kinase, putative,serine/threonine-protein kinase Nek1, putative | 0.0022 | 1 | 0.5 |
Trichomonas vaginalis | STE family protein kinase | 0.0022 | 1 | 0.5 |
Plasmodium vivax | serine/threonine-protein kinase Nek1, putative | 0.0022 | 1 | 0.5 |
Giardia lamblia | Kinase, NEK | 0.0022 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 8.1 nM | BindingDB_Patents: Kinase Assay. PBK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.